Compare PRE & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | ACIU |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | Hong Kong | Switzerland |
| Employees | 285 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.3M | 288.0M |
| IPO Year | N/A | 2015 |
| Metric | PRE | ACIU |
|---|---|---|
| Price | $19.86 | $2.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $30.50 | $10.00 |
| AVG Volume (30 Days) | ★ 277.9K | 266.5K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $108.69 | $706.75 |
| Revenue Next Year | $58.68 | $321.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.88 | $1.65 |
| 52 Week High | $23.63 | $4.00 |
| Indicator | PRE | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 24.95 |
| Support Level | $12.92 | $2.03 |
| Resistance Level | $21.72 | $3.92 |
| Average True Range (ATR) | 1.66 | 0.17 |
| MACD | 0.45 | -0.06 |
| Stochastic Oscillator | 73.33 | 3.06 |
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.